MedTrace Logo

The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction

NCT00143507 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10917

Last updated 2018-04-12

Study results available
· View outcomes & findings →

Summary

The aim of this study is to test whether ivabradine is able to reduce cardiovascular events when given to patients with coronary artery disease and impaired heart function.

Conditions

  • Coronary Disease
  • Ventricular Dysfunction, Left

Interventions

DRUG

Ivabradine

DRUG

Placebo

Sponsors & Collaborators

  • Institut de Recherches Internationales Servier

    lead OTHER

Principal Investigators

  • Kim Fox, MD · Royal Brompton National Heart and Lung Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00143507 on ClinicalTrials.gov